Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119

Journal of Thoracic Oncology

Volumn 2, Issue 6, 2007, Pages 526-530

  Akerley, Wallace ^a   McCoy, Jason ^b   Hesketh, Paul J ^c   Goodwin, J Wendall ^d   Bearden, James D ^e   Atkins, James N ^f   Chansky, Kari ^b   Crowley, John J ^b   Gandara, David R ^g  

^a UNIVERSITY OF UTAH   (United States)

^b Statistical Center   (United States)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

^d Ozarks Regional Community Clinical Oncology Program   (United States)

^e Upstate Carolina Community Clinical Oncology Program   (United States)

^f Southeast Cancer Control Consortium   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPONATREMIA; LEUKOPENIA; LUNG FUNCTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT RESPONSE; BONE TUMOR; CANCER STAGING; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447128160     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318060d2dc     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. Ca Cancer J Clin 2006;56:106-130.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years; analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
3. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.
4. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with oncedaily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.
5. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer. 1993;72:1184-1191.
6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
7. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-449.
8. Goodman GE, Crowley JJ, Blasko JC, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 1990;8:39-47.
9. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 1997;15:2840-2849.
10. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
11. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:283-285.
12. Van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001;12:557-561.
13. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer: CPT-11 Cooperative Study Group. Jpn J Cancer Chemother 1991;18:1013-1019.
14. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
15. Fujita A, Takabatake H, Tagaki S, et al. Pilot study of irinotecan in refractory small cell lung cancer. Jpn J Cancer Chemother 1995;22:889-893.
16. Noda K, Nishiwaki Y, Negoro S, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
17. Rocha Lima CS, Leong SS, Sherman CA, et al. Phase I study of irinotecan and gemcitabine in patients with solid tumors. Cancer Ther 1999;2:58-66.
18. Rocha Lima C, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-1191.
19. Bahadori HR, Lima CM, Green MR, et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-5428.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
21. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
23. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.